Monopar Therapeutics

Listed Company

MNPRCIK 0001645469NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

Net Income

—

Total Assets

—

Equity

—

Shares Out

6.70M

Op. Cash Flow

$-12.20M

Business

Monopar Therapeutics is a clinical-stage biopharma company developing a treatment for Wilson disease and a pipeline of uPAR-targeted radiopharmaceuticals for oncology. Its main product candidates include ALXN1840, an investigational oral therapy for Wilson disease, and MNPR-101 conjugates (MNPR-101-Zr, -Lu, and -Ac) for imaging and radiotherapeutic use. The company operates two principal programs—its Wilson disease development program and its MNPR-101 radiopharmaceutical program—built through in-house research and licensing. It conducts clinical trials in multiple countries (including the U.S. and Australia), pursues worldwide development and commercialization rights, and relies on third-party manufacturers and clinical sites for distribution and production.

Summary from filing dated 2025-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	10	13	6	8	6
General and administrative	7	3	3	3	3
Total operating expenses	17	16	9	11	9
Loss from operations	−17	−16	−9	−11	−9
Other income	0	171,282	0	—	—
Interest income	3	404,020	429,039	—	—
Net loss	−14	−16	−8	−11	−9
Foreign currency translation (loss) gain, net	−4,189	1,630	−17,272	−2,937	4,713
Unrealized gain on investments, net	99,586	48,494	−5,802	15,039	—
Comprehensive loss	−14	−16	−8	−11	−9
Basic and diluted (in dollars per share)	−1.85	−4.11	−3.04	−0.83	—
Basic and diluted** (in shares)	7	4	3	13	12

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	62	46	7	8	20
Investments	79	14	0	5	0
Other current assets	63,745	78,869	66,433	45,982	217,745
Total current assets	140	60	7	13	21
Operating lease right-of-use asset	254,921	0	12,646	61,228	0
Total assets	141	60	7	13	21
Accounts payable, accrued expenses and other current liabilities	3	2	2	3	2
In-process R and D accrued expenses	0	3	0	—	—
Total current liabilities	3	5	2	3	2
Operating lease liability - non-current	154,920	0	0	8,408	0
Total liabilities	3	5	2	3	2
Commitments and contingencies (Note 9)	—	—	—	—	—
Common stock, par value of $0.001 per share, 40,000,000 shares authorized, 6,692,140 and 6,102,560 shares issued and outstanding at December 31, 2025, and December 31, 2024, respectively**	6,692	6,103	2,981	12,947	12,598
Additional paid-in capital	227	131	66	62	—
Accumulated other comprehensive income	131,389	35,992	−14,132	8,942	−3,160
Accumulated deficit	−90	−76	−60	−52	−41
Total stockholders equity	138	55	6	10	19
Total liabilities and stockholders equity	141	60	7	13	21

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation expense	5	1	2	2	—
Issuance of common stock to Alexion Pharmaceuticals, Inc	0	5	0	—	—
Net amortization of investment discounts and premiums	−716,464	−9,016	—	—	—
Other current assets	15,404	−12,776	−20,410	171,755	−86,198
Accounts payable, accrued expenses and other current liabilities	388,218	506,791	−1	1	—
In-process R&D accrued expenses	−3	3	0	—	—
Operating lease right-of-use assets and liabilities, net	−9,432	4,238	0	−4,238	—
Net cash used in operating activities	−12	−6	−8	−7	−7
Purchase of short-term investments	−87	−15	−8	−5	—
Maturities of short-term investments	24	985,730	13	0	—
Net cash used in investing activities	−63	−14	5	−5	0
Cash proceeds from the sales of common stock under a Capital on DemandTM Sales Agreement, net of commissions, fees and expenses	0	4	2	109,337	—
Taxes paid related to net share settlement of vested restricted stock units	−1	−104,220	−46,969	−76,633	—
Cash proceeds from the issuance of common stock upon exercise of stock options	565,171	84	0	169	17,478
Net proceeds from issuance of common stock and concurrent issuance of pre-funded warrants upon public offering, net of offering costs	127	55	—	—	—
Repurchase of common stock	−35	0	—	—	—
Net cash provided by financing activities	92	59	2	32,873	11
Net increase in cash and cash equivalents	16	39	−920,114	−12	4
Effect of exchange rate and valuation changes on cash equivalents	97,266	494	−16,796	−3,478	—
Lease liability arising out of obtaining right-of-use asset	291,429	0	—	—	—
Accrued financing fees	0	144,588	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro